This second episode of Expose MASH [formerly NASH] will deep dive into how metabolic syndrome can contribute to liver disease. Our experts will explore why MASH is a cardiometabolic disorder and how this new perspective on liver disease can lead to improvements in identifying at-risk patients and managing cardiometabolic comorbidities. Join us as we navigate through this episode, offering a deeper understanding of the intersection between cardiometabolic dysfunction and liver health.
What is the connection between cardiometabolic dysfunction and MASH? Please join experts Mazen Noureddin, MD, MHS (Transplant Hepatologist and Professor of Medicine at Houston Methodist Hospital), Meagan Gray, MD (Transplant Hepatologist and Assistant Professor of Medicine at the University of Alabama at Birmingham) and Marcelo Kugelmas, MD, FAASLD, FACP (Director of Hepatology and Research at South Denver Gastroenterology), as they discuss the latest perspectives on MASH and how it can lead to improvements in patient care. The experts will provide insights on how to best use current guidelines to identify at-risk patients and how they collaborate with other specialists to manage underlying cardiometabolic risk factors.
This program is intended for clinicians in the US. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
Mazen Noureddin, MD, MHS
Transplant Hepatologist and Professor of Medicine
Houston Methodist Hospital
Houston, TX
Meagan Gray, MD
Transplant Hepatologist and Assistant Professor of Medicine
University of Alabama at Birmingham
Birmingham, AL
Marcelo Kugelmas, MD, FAASLD, FACP
Director of Hepatology and Research
South Denver Gastroenterology
Englewood, CO
Click here for full reference list
References
American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of care in diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S52-S76.
Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab. 2020;3(4):e00112.
Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings. Endocr Pract. 2022;28(5):528-562.
Dezső K, Paku S, Kóbori L, Thorgeirsson SS, Nagy P. What makes cirrhosis irreversible?-Consideration on structural changes. Front Med (Lausanne). 2022;9:876293.
Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547-1554.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133.
Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161(5):1657-1669.
Kidney Disease and Diabetes, American Heart Association. Accessed May 7, 2024. https://www.heart.org/en/health-topics/diabetes/diabetes-complications-and-risks/kidney-disease--diabetes
Moorman AC, Xing J, Rupp LB, et al. CHeCS Investigators. Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities. Am J Manag Care. 2019;25(8):369-374.
Nadolsky K, Cryer DR, Articolo A, Fisher T, Schneider J, Rinella M. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey. Ann Med. 2023;55(1):2211349.
Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556.
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.
Schattenberg JM, Lazarus JV, Newsome PN, et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis. Liver Int. 2021;41(6):1227-1242.
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378.
Wong RJ, Tran T, Kaufman H, Niles J, Gish R. Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis. PLoS One. 2019;14(8):e0220612.
Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review